Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B

Table 1 Comparison of clinical data in the two groups

	Hepatic fibrosis group (n = 245)	Control group (n = 93)	t/χ2 value	P value
Sex (male/%)	136/55.51	45/48.39	1.375	0.241
Age	40.31 ± 10.47	37.82 ± 13.72	1.785	0.075
SWV (m/s)	3.02 ± 0.80	1.52 ± 0.62	16.310	0.000
ALT (U/L)	52.23 ± 26.02	46.87 ± 87.45	1.487	0.138
AST (U/L)	41.12 ± 12.72	36.14 ± 14.52	1.607	0.109
AST/ALT	0.93 ± 0.41	0.74 ± 0.23	4.221	0.000
PLT (109/L)	184.02 ± 02.21	192.37 ± 37.42	1.220	0.223
TBIL (μmol/L)	19.83 ± 9.83	18.75 ± 8.72	1.570	0.117
HA (μg/L)	113.24 ± 24.78	63.23 ± 23.54	15.748	0.000
LN (μg/L)	36.21 ± 21.34	34.21 ± 10.28	1.485	0.139
CIV (μg/L)	33.28 ± 28.20	20.89 ± 9.56	4.144	0.000
PIIINP (μg/L)	36.29 ± 29.45	32.87 ± 2.32	1.100	0.272
APRI	0.85 ± 0.61	0.62 ± 0.52	3.219	0.001
FIB-4	1.63 ± 0.89	1.17 ± 0.62	4.578	0.000

SWV: Shear wave velocity; ALT: Alanine aminotransferase; AST: Aspartate transaminase; PLT: Blood platelet; TBIL: Total bilirubin; HA: Hyaluronic acid; LN: Laminin; CIV: Type IV collagen; PIIINP: Type III procollagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.

Table 2 Binary logistic regression analysis of risk factors associated with hepatic fibrosis

Influencing factors	B	SE	Wald	OR	95%CI	P value
SWV	0.931	0.325	5.024	2.537	1.342-4.797	0.025
AST/ALT	0.561	0.286	2.765	1.752	0.896-3.069	0.056
HA	0.838	0.127	5.352	2.311	1.802-2.964	0.021
CIV	0.466	0.183	4.042	1.593	1.113-2.280	0.046
APRI	0.719	0.312	4.642	2.053	1.114-3.784	0.037
FIB-4	0.433	0.287	2.973	1.542	0.879-2.706	0.063

SWV: Shear wave velocity; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HA: Hyaluronic acid; CIV: Type IV collagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.

Table 3 Diagnostic efficacy of various indicators in the diagnosis of hepatic fibrosis

Index	AUC	Best diagnostic point	Sensitivity, %	Specificity, %
SWV	0.873	1.66 m/s	86.90	88.20
AST/ALT	0.803	0.920	55.90	95.70
HA	0.848	87.79 μg/L	91.00	79.60
CIV	0.784	30.36 μg/L	52.70	98.90
APRI	0.789	0.787	57.60	86.00
FIB-4	0.797	1.157	80.00	65.60

SWV: Shear wave velocity; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HA: Hyaluronic acid; CIV: Type IV collagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.

Table 4 Correlation between serological data and the degree of hepatic fibrosis

Index	r	P value
SWV (m/s)	0.767	0.000
HA (μg/L)	0.711	0.000
AST/ALT	0.684	0.000
CIV (μg/L)	0.681	0.000
APRI	0.634	0.000
FIB-4	0.702	0.000

SWV: Shear wave velocity; HA: Hyaluronic acid; ALT: Alanine aminotransferase; AST: Aspartate transaminase; CIV: Type IV collagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.

Table 5 Multiple linear regression analysis of the degree of hepatic fibrosis

	Non-standardized coefficient		Standard coefficient	t	Sig.
	B value	Standard error	B value
Constant	-4.046	0.209	-	-19.365	0.000
SWV	1.024	0.148	0.2200	6.930	0.000
AST/ALT	1.170	0.190	0.3231	7.861	0.000
HA	0.011	0.005	0.2010	7.126	0.000
CIV	0.020	0.003	0.1980	5.749	0.000
APRI	0.719	0.102	0.1880	7.040	0.000
FIB-4	0.379	0.088	0.1490	4.304	0.000

SWV: Shear wave velocity; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HA: Hyaluronic acid; CIV: Type IV collagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.